Insmed’s COVID-19 Response
As we navigate the global COVID-19 pandemic, Insmed is taking steps to ensure the health and safety of the patients we serve as well as our own employees. We are also doing our part to support our local communities and aid in the global containment effort.
Here are a few updates on our business:
In April, Insmed announced that we are funding and providing clinical drug supply for the STOP-COVID19 (Superiority Trial of Protease inhibition in COVID-19) trial, an investigator-initiated study of brensocatib (formerly known as INS1007) in hospitalized patients with COVID-19. The mechanism of action of brensocatib, a candidate that we are advancing into Phase 3 development for patients with bronchiectasis, suggests that it may have broad applicability in a range of neutrophil-mediated diseases. This could include acute respiratory distress syndrome (ARDS), a severe outcome of COVID-19. Based on this rationale, we are pleased to support this investigator-initiated trial. In parallel, we continue to pursue an in vivo mouse model to better understand the potential of brensocatib in preventing ARDS.
Since the start of the pandemic, Insmed has worked hand in hand with the biopharmaceutical industry to support evolving needs in our communities. Some of the ways we have lent support include donating personal protective equipment to those on the front lines, sharing iPads with local hospitals to enable critically ill patients to see their loved ones, and raising money for the Community FoodBank of NJ to support local families facing food insecurity due to the crisis. We continue to look for ways we can be of service during this challenging time.
Our supply chain is strong, with no disruptions to date in the production of our approved medicine or our pipeline candidates. We currently have enough active pharmaceutical ingredient of our approved medicine to meet anticipated global requirements through the end of 2022. Our third-party manufacturers continue to operate to ensure an uninterrupted supply of medication while taking all necessary precautions to protect their workers’ safety.
We know that patients living with refractory Mycobacterium avium complex (MAC) lung disease may feel especially concerned at this time. We encourage you to speak with your doctor for specific medical advice related to COVID-19. For patients in the U.S. taking our approved product, our patient services team remains available and can be reached at 1-833-ARIKARE (1-833-274-5273) to support enrolled patients. In addition, our Arikares Trainers can provide remote device training for new patients who initiate treatment with our approved product.
The majority of Insmed employees continue to work remotely to aid in the global containment effort. In the U.S., field-based employees who are comfortable calling on their customers and work in states that permit such activity are able to do so on a voluntary basis as of June 1, 2020. A small group of essential workers has also returned to the workplace on a voluntary basis and with precautionary measures in place. We are closely monitoring government guidance in all of the geographies in which we operate and will consider having employees return to the workplace on a voluntary basis as local guidance allows and with employees’ comfort and safety at the forefront. Above all, we are deeply committed to ensuring that our employees have the support they need during this unprecedented time.
Healthcare Professionals (HCPs)
With many of our field-based employees out of the field and HCPs continuing to focus on critical relief efforts, we remain dedicated to supporting HCPs’ needs through remote, virtual interactions. HCPs who have specific questions should call 1-844-4-INSMED (1-844-446-7633) or email firstname.lastname@example.org.
Insmed is working hand in hand with the entire biopharmaceutical industry to support evolving needs in the fight against COVID-19. We know this is a rapidly changing situation. We are closely monitoring the latest information so we can do everything in our power to protect the health of the patients we serve and the employees who enable us to do so.